US Drug Recall Register

FDA Drug Recalls

17,898 recalls, newest first

Class III · Low risk Terminated

Lisinopril Tablets USP 20 mg

Reason Presence of Foreign Tablets: Potential of stray tablet(s) of Amlodipine Besylate 10 mg Tablet within the recalled lots

NCS Healthcare of Kentucky Inc NDC 0615-7718-05 D-0114-2024
Class III · Low risk Terminated

Buspirone Hydrochloride Tabs USP 10 mg

Reason Presence of Foreign Tablets: Potential of stray tablet(s) of Amlodipine Besylate 10 mg Tablet within the recalled lots

NCS Healthcare of Kentucky Inc NDC 0615-7718-05 D-0113-2024
Class II · Moderate risk Terminated

Extended Phenytoin Sodium Capsules

Reason Failed Dissolution Specifications

Amneal Pharmaceuticals of New York, LLC NDC 65162-212-10 D-0090-2024
Class III · Low risk Terminated

Mycophenolate Mofetil for Oral Suspension

Reason Defective Container: The adaptor does not fit into the neck of the bottle after reconstitution with water.

VistaPharm LLC NDC 66689-307-08 D-0093-2024
Class I · High risk Terminated

Phenytoin Oral Suspension

Reason Failed Content Uniformity Specifications

The Harvard Drug Group LLC dba Major Pharmaceuticals and Rugby Laboratories NDC 0904-7079-24 D-0153-2024
Class III · Low risk Terminated

Esomeprazole Magnesium Delayed-Release Capsules

Reason Failed Impurities/Degradation Specifications:Out of Specification result reported for the test of organic impurities for the drug product,at the 18 month time point in long term stability study (25¿C/60% RH).

Glenmark Pharmaceuticals Inc., USA NDC 68462-390-30 D-0112-2024
Class II · Moderate risk Ongoing

Ranolazine Extended-Release Tablets 500mg

Reason Failed Dissolution Specifications: Out of specification for dissolution.

Glenmark Pharmaceuticals Inc., USA NDC 68462-319-60 D-0092-2024
Class I · High risk Ongoing

Kuka Flex Forte caplets

Reason Marketed Without an Approved NDA/ANDA: products found to contain undeclared diclofenac.

Botanical Be D-0226-2024
Class I · High risk Ongoing

Reumo Flex caplets

Reason Marketed Without an Approved NDA/ANDA: products found to contain undeclared diclofenac.

Botanical Be D-0225-2024
Class II · Moderate risk Terminated

Tiglutik

Reason Failed Viscosity Specifications: Out-of-specification test results for viscosity

Itf Pharma INC D-0115-2024
Class II · Moderate risk Ongoing

Equate Hand Sanitizer

Reason Sub Potent and Super Potent Product: During an impact assessment of the DOP Hand Sanitizer product, it was identified that several lots distributed did not comply with the finished good acceptance criteria established.

Omega & Delta Co., Inc. D-0105-2024
Class II · Moderate risk Ongoing

DOP Instant Hand Sanitizer

Reason Sub Potent and Super Potent Product: During an impact assessment of the DOP Hand Sanitizer product, it was identified that several lots distributed did not comply with the finished good acceptance criteria established.

Omega & Delta Co., Inc. D-0104-2024
Class II · Moderate risk Ongoing

DOP Instant Hand Sanitizer

Reason Sub Potent and Super Potent Product: During an impact assessment of the DOP Hand Sanitizer product, it was identified that several lots distributed did not comply with the finished good acceptance criteria established.

Omega & Delta Co., Inc. D-0103-2024
Class III · Low risk Ongoing

Oxaydo

Reason Sub-potent Drug: Lower potency than labeled.

Zyla Life Sciences US Inc. D-0094-2024
Class II · Moderate risk Terminated

Liothyronine Sodium Tablets

Reason Failed Impurities/Degradation Specifications.

Sun Pharmaceutical Industries INC NDC 62756-590-88 D-0084-2024
Class II · Moderate risk Terminated

Liothyronine Sodium Tablets

Reason Failed Impurities/Degradation Specifications.

Sun Pharmaceutical Industries INC NDC 62756-589-88 D-0083-2024
Class III · Low risk Terminated

Opium Tincture

Reason Subpotent Drug

Edenbridge Pharmaceuticals, LLC NDC 42799-217-01 D-0080-2024
Class II · Moderate risk Completed

Oxybutynin Chloride Extended-Release Tablet USP

Reason Failed Dissolution Specifications-out-of-specification (OOS) test results observed for dissolution at the 6 month long term time point.

Zydus Pharmaceuticals (USA) Inc NDC 68382-257-01 D-0098-2024
Class II · Moderate risk Completed

Oxybutynin Chloride Extended-Release Tablet USP

Reason Failed Dissolution Specifications-out-of-specification (OOS) test results observed for dissolution at the 6 month long term time point.

Zydus Pharmaceuticals (USA) Inc NDC 68382-256-01 D-0097-2024
Class II · Moderate risk Completed

Oxybutynin Chloride Extended-Release Tablet USP

Reason Failed Dissolution Specifications-out-of-specification (OOS) test results observed for dissolution at the 6 month long term time point.

Zydus Pharmaceuticals (USA) Inc NDC 68382-255-01 D-0096-2024
Class II · Moderate risk Terminated

Strong Iodine Solution U.S.P.

Reason CGMP Deviations: Recall due to the absence of USP CGMP compendial requirements.

Safecor Health, LLC NDC 48433-230-15 D-0082-2024
Class I · High risk Ongoing

Elcys

Reason Presence of Particulate Matter: Silicone

Exela Pharma Sciences LLC NDC 51754-1007-1 D-0118-2024